Data Readout

Rein Therapeutics' LTI-03 IPF safety data due as trial re-enrolls after FDA hold

The Phase 2 RENEW trial resumed U.S. enrollment after an FDA clinical hold, with initial safety and tolerability data expected as the sole clinical-stage test of a Caveolin-1 mechanism in IPF.

By AppliedXLJuly 13, 2026Trial NCT06968845

Executive Summary

Rein Therapeutics is heading toward its first clinical readout of LTI-03 in idiopathic pulmonary fibrosis after the FDA lifted a clinical hold that had paused the trial, with the primary question centered on tolerability rather than efficacy.
Enrollment restarted at the trial's original target after the hold was resolved, and the study returned to active recruitment without any change in planned size, a clean operational restart rather than a scaled-back program.
No other clinical-stage program targets this mechanism in this disease, so the readout will be judged against the standard-of-care landscape and the trial's own tolerability bar rather than against a direct rival.
Because the primary endpoint is adverse-event incidence, the data will show whether an inhaled peptide can be dosed safely enough to let its lung-function and fibrosis-imaging measures accumulate signal over time.

The catalyst

Rein Therapeutics (NASDAQ: RNTX) expects initial topline data from Study LTI-03-2001, the Phase 2 RENEW trial of LTI-03, an inhaled peptide therapy derived from Caveolin-1 biology, in patients with idiopathic pulmonary fibrosis. The trial is registered as NCT06968845, targets enrollment of 120 adults, and lists a primary endpoint of safety and tolerability measured by the incidence of treatment-emergent adverse events. Secondary endpoints track change in forced vital capacity, percent predicted FVC, and lung fibrosis by high-resolution CT. Rein's chief executive, Brian Windsor, said the FDA's decision to lift the hold "clears the path for us to resume enrollment and continue advancing LTI-03 through our global Phase 2 program". Rein+1

Probability of Success

Endpoint Met24%

Completes82%

Clinical Significance28%

Regulatory49%

The restart

The FDA placed a full clinical hold on the U.S. arm of RENEW before lifting it in late 2025 after reviewing Rein's Complete Response submission, which the agency said resolved all of its concerns. The trial's registry status moved from Recruiting to Active, not recruiting in June 2025 and back to Recruiting in February 2026, alongside a primary completion date change from May 2027 to September 2027. Enrollment held flat at its original 120-patient target through the restart, a routine hold that the trial's own operational baseline flags as unremarkable. Rein said it would resume enrollment across roughly 20 U.S. sites, adding to about 30 existing sites in the United Kingdom, Germany, Poland, and Australia. Rein+1

What the readout can establish

With a randomized, placebo-controlled design (two experimental and two placebo arms) and a safety-first primary endpoint, the trial is built to answer a tolerability question before an efficacy one. A tolerability signal that supports continued dosing would let the lung-function and imaging secondary endpoints, changes in FVC and HRCT-measured fibrosis, accumulate as the more consequential efficacy readout in later data cuts. LTI-03 has received Orphan Drug Designation in the United States, a designation that signals unmet need in the disease rather than a predictor of the trial's outcome. Rein

The competitive frame

No other clinical-stage program in idiopathic pulmonary fibrosis shares LTI-03's Caveolin-1 target, and the trial is the only Phase 2 or later asset built on that mechanism in this disease. The nearest comparators in the field, nintedanib and pirfenidone-class therapies and later-stage entrants such as deupirfenidone, nerandomilast, and HEC585, work through unrelated mechanisms including VEGFR, PDE4B, and small-molecule antifibrotic pathways, so they inform the standard-of-care backdrop without competing on the same biology. IPF carries a median survival of three to five years from diagnosis despite currently approved therapies aimed at slowing progression, underscoring why a dual-acting mechanism aimed at both limiting fibrosis and supporting lung repair would be differentiated if the tolerability and downstream efficacy signals hold up. Rein

Timing

Rein first guided to a Q3 2026 window for initial topline data in its November 2025 disclosure, and a later guidance update pushed the outer bound to H2 2026 (through December 31, 2026). Both windows remain open as of the current date. The trial's protocol history shows one primary completion date change and no endpoint amendments since the study was first posted, a stability profile the registry's own churn metric labels routine. Rein

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.